Article
Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib.
Cancer reports (Hoboken, N.J.) - 1 Dec 2025
Kagawa Kei, Masuda Takeshi, Shimoji Kiyofumi, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Nakashima Taku, Iwamoto Hiroshi, Hamada Hironobu, Hattori Noboru
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40%-50% of patients with lung adenocarcinoma in Asian populations and in around 10% of patients in Western populations. Among these, the EGFR L861R mutation is uncommon and undetectable using conventional polymerase chain reaction methods. Recently, clinically available next-generation sequencing (NGS) has been used to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.